Current advancements and future perspectives of immunotherapy in colorectal cancer research

5-Fluorouracil (5-FU) is the first-line chemotherapy drug for colorectal cancer but most of the patients get resistant to the drug on a longer course of treatment. After the successful use of immunotherapy in melanoma treatment, it was explored with enthusiasm in different types of solid cancers inc...

Full description

Saved in:
Bibliographic Details
Published in:European journal of pharmacology 2021-02, Vol.893, p.173819-173819, Article 173819
Main Authors: Kishore, Chandra, Bhadra, Priyanka
Format: Article
Language:English
Subjects:
Animals
Antibodies, Bispecific - therapeutic use
Antineoplastic Agents, Immunological - therapeutic use
Chemotherapy, Adjuvant - trends
Colorectal cancer
Colorectal Neoplasms - immunology
Colorectal Neoplasms - metabolism
Colorectal Neoplasms - therapy
Diffusion of Innovation
dMMR-MSI-H
Humans
Immune checkpoint inhibitor
Immune Checkpoint Inhibitors - therapeutic use
Immunotherapy
Immunotherapy - adverse effects
Immunotherapy - trends
Immunotherapy, Adoptive - trends
Neoadjuvant Therapy - trends
pMMR-MSI-L
T-cells
Tumor Microenvironment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:5-Fluorouracil (5-FU) is the first-line chemotherapy drug for colorectal cancer but most of the patients get resistant to the drug on a longer course of treatment. After the successful use of immunotherapy in melanoma treatment, it was explored with enthusiasm in different types of solid cancers including colorectal cancer. Nivolumab and pembrolizumab (Programmed cell death-1 blocking antibodies) have shown efficacy in the mismatch repair deficient high microsatellite instability (dMMR-MSI-H) subtype of metastatic colorectal cancer (CRC) patients. Immunotherapy has shown long time remission in a subset of metastatic CRC patients. The molecular mechanism and emerging roles of immunotherapy in colorectal cancer are explored in this review article and future directions for the proper utilization of the development in immunobiology are suggested.
ISSN:0014-2999
1879-0712
DOI:10.1016/j.ejphar.2020.173819